Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;140(12):2319-2325.e1.
doi: 10.1016/j.jid.2020.09.020.

Research Techniques Made Simple: Preclinical Development of Combination Antitumor Targeted Therapies in Dermatology

Sara Yumeen  1 , Fatima N Mirza  2 , Julia M Lewis  2 , Michael Girardi  3
Affiliations
Free article

Research Techniques Made Simple: Preclinical Development of Combination Antitumor Targeted Therapies in Dermatology

Sara Yumeen et al. J Invest Dermatol. 2020 Dec.
Free article

Abstract

The identification and application of targeted therapies that inhibit critical pathways in malignant cells have shown tremendous promise for improving clinical outcomes for patients with advanced cutaneous malignancies. However, tumor cell heterogeneity, development of drug resistance, and risks of off-target effects remain barriers to prolonged remission and definitive cure. Herein, we describe the potential that combinations of antitumor targeted agents may offer in overcoming these challenges and detail techniques whereby promising combination regimens can be identified and further evaluated preclinically. Cancer cell lines and primary patient-derived malignant cells can be utilized to perform dose-response screenings in vitro for individual targeted agents before moving toward the evaluation of potential synergistic combinations. Mathematical analyses, including the Chou-Talalay method, determine combination indices and Hill slopes that permit relative comparisons among various drug combinations by quantification of synergistic activities. Further preclinical in vivo evaluation of promising single versus combination regimens may be studied in relevant mouse models of cutaneous malignancy. Ultimately, the formulation of combination targeted therapy regimens may be more broadly effective and less toxic, helping to better inform clinical trial design and prioritization.

PubMed Disclaimer

Similar articles

See all similar articles

Publication types

MeSH terms

LinkOut - more resources